Search results
Results From The WOW.Com Content Network
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...
What may cause Lexapro weight gain? ... “A lower, but still high enough to be clinically effective dose, can reduce weight gain.” ... stomach pain. excessive tiredness. dry mouth.
It can cause burning pain in the mouth, throat and stomach, bloody vomiting, headache, muscle cramps, cramps and convulsions, drop in blood pressure, heart failure, shock, coma, and possible death. Mean lethal dose by ingestion of oxalates is 10-15 grams/kilogram of body weight (per MSDS ).
In some cases, powdered ginger root is a main flavoring agent in ginger ale, leading people to believe that soda is good for stomach relief. But most popular ginger ale sodas contain little to no ...
The authors of the paper hypothesized that acute oxalate nephropathy is an underdiagnosed cause of kidney failure and suggested thorough examination of patient dietary history in cases of unexplained kidney failure without proteinuria (an excess of protein in the urine) and with large amounts of calcium oxalate in urine sediment. [18]
Ginger contains 5-HT 3 antagonists gingerols, shogaols, [18] and galanolactone. [19] Preliminary clinical data suggests ginger may be effective for treatment of nausea and/or vomiting in a number of settings. [20] [21] [22] Emetrol is also claimed to be an effective antiemetic. Propofol is given intravenously. It has been used in an acute care ...
Many athletes need to consume an increased number of calories per day to maintain and/or gain weight and muscle mass due to the high amount of calories burned during their sport and training ...
Thiazolidinediones may cause slight weight gain but decrease "pathologic" abdominal fat (visceral fat), and therefore may be prescribed for diabetics with central obesity. [115] Thiazolidinedione has been associated with heart failure and increased cardiovascular risk; so it has been withdrawn from the market in Europe by EMA in 2010. [116]